Stiripentol

Bibliography

• SHEN DD, LEVY RH, SAVITCH JL, BODDY AV, TOMBRET F, LEPAGE F: Comparative anticonvinsant potency and pharmacokinetics of (÷)-and enantiomers of stiripentol. Epilepsy Res. (1992)12(1):29–36.
   PubMed Web of Science ®Google Scholar
• ARENDS RH, ZHANG K, LEVY RH, BAILLIE TA, SHEN DD: Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect. Epilepsy Res. (1994) 18(2):91–96.
   PubMed Web of Science ®Google Scholar
• POISSON M, HUGUET F, SAVATTIER A, BAKRI-LOGEAIS F, NARCISSE G: A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arznehnittelforschung (1984) 34(2):199–204.
   PubMed Web of Science ®Google Scholar
• SHEN DD, LEVY RH, MOOR MJ, SAVITCH JL: Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat. Epilepsy Res. (1990) 7(1):40–8.
   PubMed Web of Science ®Google Scholar
• LOCKARD JS, LEVY RH, RHODES PH, MOORE DF: Stiripentol in acute/chronic efficacy tests in monkey model. Epliepsia (1985) 26(6):704–712.
   PubMed Web of Science ®Google Scholar
• WEGMANN R, ILIES A, AUROUSSEAU M, PATTE F: Pharmaco-cellular enzymology of the mode of action of Stiripentol during cardiazolic epilepsia. IV. Cellular and tissular repartition of 3H-stiripentol (author's trans°. Cell Mol. Biol. Incl. Cyto. Enzymol (1979) 24(1):51–60.
   Google Scholar
• LEVY RH, LOISEAU P, GUYOT M, BLEHAUT HM, TOR J, MORELAND TA: Michaelis-Menten kinetics of stiripentol in normal humans. Epilepsia (1984) 25(4):486–491.
   PubMed Web of Science ®Google Scholar
• TRAN A, REY E, PONS G et al: Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clia Pharmacol. Ther. (1997) 62(5):490–504.
   PubMed Web of Science ®Google Scholar
• PEREZ J, CHIRON C, MUSIAL C et al.: Stiripentol: efficacy and tolerability in children with epilepsy. Epliepsia (1999) 40(10:1618–1626.
   PubMedGoogle Scholar
• CHIRON C, MARCHAND MC, TRAN A et al: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet (2000) 356(9242):1638–1642.
   PubMed Web of Science ®Google Scholar
• ••STP showed antiepileptic efficacy in SMEIin association with CLB and valproate in this study.
   Google Scholar
• LEVY RH, RETTEMEIER AW, ANDERSON GD et al: Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. (1990) 48(3):225–235.
   PubMed Web of Science ®Google Scholar
• TRAN A, VAUZELLE-KERVROEDAN F, REY E et al.: Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur. Clin. Pharmacol. (1996) 50(6):497–500.
   Web of Science ®Google Scholar
• •Good review of the effects of STP in combination with CBZ.
   Google Scholar
• CAZALI N, TRAN A, TRELUYER JM et al.: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br. J. Cliii. Pharmacol. (2003) 56(5):526–536.
   Web of Science ®Google Scholar
• CHIRON C, TONNELIER S, REY E et aL:Stiripentol in childhood partial epilepsy: a randomized placebo-controlled trial with enrichment and withdrawal design. Child Neurol (2005):(In Press).
   Google Scholar
• LEVY RH, LOISEAU P, GUYOT M, BLEHAUT HM, TOR J, MORELAND TA: Stiripentol kinetics in epilepsy: nonlinearity and interactions. Pharmacol. Ther. (1984) 36(5):661–669.
   Web of Science ®Google Scholar
• FARWELL JR, ANDERSON GD, KERR BM, TOR JA, LEVY RH:910Expert Op/n. lnvestig. Drugs (2005) 14(7) Stiripentol in atypical absence seizures in children: an open trial. Epllepsia (1993) 34(2):305–311.
   Google Scholar
• TRAN A, TRELUYER JM, REY E et al: Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat. Toxicol Appl. Pharinacol (2001) 170(3):145–152.
   PubMed Web of Science ®Google Scholar
• ••Reviews the effects of STP onacetaminophen levels in rats.
   Google Scholar
• FINNELL RH, KERR BM, VAN WAES M, STEWARD RL, LEVY RH: Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epllepsia (1994) 35(1):141–148.
   PubMed Web of Science ®Google Scholar
• FINNELL RH, BENNETT GD, SLATTERY JT, AMORE BM, BAJPAI M, LEVY RH: Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology (1995) 52(6):324–332.
   PubMedGoogle Scholar
• FINNELL RH, BENNETT GD, MATHER GG, WLODARZCYK B, BAJPAI M, LEVY RH: Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod. Toxicol (1999) 13(2):85–91.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, NIGRO M, SACHDEO R et al.: Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology (2000) 54(12):2237–2244.
   Google Scholar
• •Study evaluating the efficacy and safety of CBZ in children with partial seizures.
   Google Scholar
• SACHDEO RC, GLAUSER TA, RITTER F, REIFE R, LIMP, PLEDGER G: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology (1999) 52(9):1882–1887.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating that adjunctive therapy with topiramate was effective in reducing the number of drop attacks and major motor seizures in Lennox-Gastaut syndrome.
   Google Scholar
• THANH TN, CHIRON C, DELLATOLAS G et al.: Efficacité et tolerance a long terme du stiripentol darts le traitement de répilepsie myoclonique sévère du nourrisson (syndrome de Dravet). Arch. Pediatr. (2002) 9(10:1120–1127.
   PubMedGoogle Scholar
• NABBOUT R, GENNARO E, DALLA BB et al.: Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology (2003) 60(12):1961–1967.
   PubMed Web of Science ®Google Scholar
• •Infant SMEI patients were evaluated for SCN1A mutations.
   Google Scholar
• GUERRINI R, DRAVET C, GENTON P, BELMONTE A, KAMINSKA A, DULAC 0: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia (1998) 39(5):508–512.
   PubMed Web of Science ®Google Scholar
• •Lamotrigine treatment was found to be inappropriate in SMEI.
   Google Scholar
• WALLACE SJ: Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. (1998) 29(2):147–154.
   PubMed Web of Science ®Google Scholar
• NIETO-BARRERA M, CANDAU R, NIETO-JIMENEZ M, CORREA A, DEL PORTAL LR: Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure (2000) 9(8):590–594.
   PubMed Web of Science ®Google Scholar
• COPPOLA G, CAPOVILLA G, MONTAGNINI A et al.: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. (2002) 49(1):45–48.
   PubMed Web of Science ®Google Scholar
• CEULEMENS B, BOEL M, CLAES L et al: Severe myoclonic epilepsy in infancy: toward an optimal treatment. I Child. Neurol (2004) 19(7):516–521.
   PubMed Web of Science ®Google Scholar
• HOLMES GL, BEN API Y: The neurobiology and consequences of epilepsy in the developing brain. Pediatr. Res. (2001) 49(3):320–325.
   PubMed Web of Science ®Google Scholar
• ••Reviews the developmental imbalancebetween excitatory and inhibitory processes in the developing brain.
   Google Scholar